Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29897387 | 1.00 | LPL (0.38) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL31636019 | 0.88 | LPL (0.42) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL4674071 | 0.86 | LPL (0.44) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL23301083 | 0.80 | LPL (0.40) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL22848280 | 0.80 | ALDH1A1 (0.42) | LPLLIPGJAK2BTKALDH1A1 | |
| SCHEMBL31125044 | 0.80 | TSHR (0.41) | LPLLIPGJAK2BTKALDH1A1 | |
| SCHEMBL29897368 | 0.80 | LPL (0.40) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL20730433 | 0.79 | LPL (0.35) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL18569315 | 0.78 | LPL (0.38) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL23301057 | 0.78 | LPL (0.41) | LPLLIPGJAK2BTKIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20240287062-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | MEDIVIR AB (SE) | 2024-02-22 | — | — | US | disclosed |
| EP-4308566-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | Tango Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425656-A | Purine derivatives as anticancer agents | 探戈医药股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230037225-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS APELIN RECEPTOR AGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-02-02 | — | — | US | disclosed |
| WO-2022236319-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022236319-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022197892-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | TANGO THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11345705-B2 | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2021084265-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021084264-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| US-20210040098-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-02-11 | — | — | US | disclosed |
| EP-3664806-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019032720-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | RRM2, TYMP, PNP | LPL 4447/4885LIPG 4853/4885JAK2 4145/4885 |
| US-11345705-B2 | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | APLNR, AP3B1, AGTR1 | LPL 1633/4885LIPG 1142/4885JAK2 2449/4885 |
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | SIK2, SIK1, SIK3 | LPL 3801/4885LIPG 1454/4885JAK2 54/4885 |
| US-20210040098-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | APLNR, APMAP, EDNRA | LPL 548/4885LIPG 213/4885JAK2 3161/4885 |
| US-20230037225-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS APELIN RECEPTOR AGONISTS | APLNR, AP3B1, AGTR1 | LPL 1633/4885LIPG 1142/4885JAK2 2449/4885 |
| US-20240287062-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | BRAF, NRAS, ABL1 | LPL 3374/4885LIPG 1365/4885JAK2 122/4885 |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | SIK2, SIK3, SIK1 | LPL 4544/4885LIPG 2630/4885JAK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.